The International Commission on the Clinical Use of Human Germline Genome Editing claims the technology is still too risky for therapeutic use.

The modification of three babies’ genes by He Jiankui drew widespread criticism from scientists.

The research, led by Russian biologist Denis Rebrikov, has not led to the birth of gene-edited babies—yet.

The authors have requested a retraction of a paper that found people with the CCR5 Δ32 variant are more likely to die sooner.

Emails reveal that a facility in Dubai and others have asked geneticist He Jiankui for help in gene-editing embryos.

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

After the reported birth of CRISPRed babies in China, experts want to take time to consider the scientific, social, ethical, and philosophical consequences of editing heritable human DNA.

After the controversy of a Chinese scientist who was involved in editing the genomes of twin girls, the country puts forth tighter guidelines.

Two studies show signs that the introduced DNA is functioning, but it’s too early to know if patients actually benefit.

Multiple researchers were aware of He Jiankui’s clinical trial before the news became public in November.

2018 closed with hubbub surrounding the purported birth of babies whose genomes had been edited using CRISPR. What will 2019 hold for CRISPR’s use in humans?

He Jiankui says he has successfully used CRISPR-Cas9 to tweak the genes of twins born earlier this month. Some independent experts are dubious.

With a built-in supply of a powerful cocaine-chomping enzyme, the transplant might also curb addiction.

The UK-based organization encourages public debate about the issue but does not recommend immediate policy change.

Brief electroporation appears to make T cells more receptive to new genetic material, which could speed the development of immunotherapies.

US researchers could become the first outside China to use the gene-editing technique in the clinic. 

The first industry-sponsored CRISPR therapy is slated to be tested in humans in 2018.

The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

The embryos, whose genes were altered by CRISPR, were not intended for implantation.